Found: 11
Select item for more details and to access through your institution.
Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis.
- Published in:
- Central European Journal of Immunology, 2019, v. 44, n. 1, p. 84, doi. 10.5114/ceji.2018.75831
- By:
- Publication type:
- Article
Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study.
- Published in:
- Stem Cells Translational Medicine, 2020, v. 9, n. 10, p. 1190, doi. 10.1002/sctm.20-0099
- By:
- Publication type:
- Article
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 925, doi. 10.1002/ajh.26207
- By:
- Publication type:
- Article
Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 3, p. E63, doi. 10.1002/ajh.26062
- By:
- Publication type:
- Article
Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 3, p. 779, doi. 10.1007/s00277-021-04434-x
- By:
- Publication type:
- Article
Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti‐myeloma treatment.
- Published in:
- International Journal of Dermatology, 2021, v. 60, n. 7, p. e271, doi. 10.1111/ijd.15504
- By:
- Publication type:
- Article
Response to Caravita di Toritto and Rago.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 2, p. 224, doi. 10.1111/ejh.13887
- By:
- Publication type:
- Article
Conditioning with melphalan 200 mg/m<sup>2</sup> and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care.
- Published in:
- European Journal of Haematology, 2022, v. 109, n. 6, p. 749, doi. 10.1111/ejh.13861
- By:
- Publication type:
- Article
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 4, p. 546, doi. 10.1111/ejh.13585
- By:
- Publication type:
- Article
Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 22, p. 20736, doi. 10.1002/cam4.6640
- By:
- Publication type:
- Article
Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.
- Published in:
- 2018
- By:
- Publication type:
- journal article